Introduction
The Hippo signalling pathway was first discovered in Drosophila as a regulator of growth. After several decades, mammalian homologues of the Hippo signalling genes of Drosophila melanogaster have been identified. The Hippo signalling pathway is a highly conserved mediator of tissue homeostasis, organ size, cell regeneration and growth [1, 2] . Recently, increasing evidence has shown that deregulation of the Hippo pathway triggers tumorigenesis through the alteration of tumour-related cellular biochemical processes, including cell proliferation, survival, polarity and cell-cell adhesion. The Hippo pathway has been reported to be tightly coupled to many human tumour types, such as breast, liver, lung, colorectal and gastric cancers [3] .
Several previous studies have revealed that miRNAs are highly involved in the regulation of the Hippo pathway, which results in various cellular processes of cancer progression; in general, the Hippo pathway Abbreviations 3 0 UTR, 3 0 untranslated-region; AREG, amphiregulin; CTGF, connective tissue growth factor; CYR61, cysteine-rich angiogenic inducer; DGCR8, DiGeorge syndrome critical region gene; EMT, epithelial-mesenchymal transition; GPCRs, G-protein-coupled receptors; HCC, hepatocellular carcinoma; IL-6, interleukin 6; IL-8, interleukin 8; ISC, intestinal stem cell; LATS1, large tumour suppressor 1; LIFR, leukaemia inhibitory factor receptor; miRNAs, microRNAs; MOB1, Mps One Binder kinase activator; Msn, Misshapen; MST1, STE20-like protein kinase 1; pre-miRNA, precursor miRNA; pri-miRNA, primary miRNA transcripts; PTEN, phosphatase and tensin homologue; RISC, RNA-induced silencing complex; TAZ, PDZ-binding motif; TEAD, TEA domain family members; YAP, Yes-associated protein; Yki, Yoekie.
plays an important role in tumorigenesis. Two downstream effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), directly control miRNA biogenesis [4] . Intriguingly, several miRNAs have been shown to target and regulate the core components of the Hippo signalling pathway.
In this review, we summarize the most recent findings regarding the crosstalk between miRNAs and the Hippo pathway in cancer-relevant biology in model organisms. Additionally, we focus on the complex regulatory networks of miRNAs and Hippo, which play a pivotal role in tumour progression. Finally, we describe potential targets for therapeutic interventions.
The Hippo pathway
The core components of the Hippo signalling pathway consist of a kinase cascade that controls the growth and homeostasis of tissues and organs during development and maintenance as well as physiological and pathological alterations in tumorigenesis. The Hippo signalling pathway is highly conserved in mammals. In sum, the mammalian central kinase components include large tumour suppressor 1 (LATS1) and LATS2, STE20-like protein kinase 1 (MST1) and MST2, and Mps One Binder kinase activator (MOB1) and SAV1 (also known as WW45). YAP and TAZ are the major downstream effectors of the Hippo kinase cascade [5, 6] . In mammals, the phosphorylation of YAP is responsible for Hippo pathway-mediated organ size and its dysregulation contributes to tumorigenesis [7] . Similarly, Yoekie (Yki), the Drosophila orthologue of YAP, is also the key transcriptional coactivator of the Hippo pathway. Nuclear accumulation and activation of Yki contribute to tissue overgrowth and stem cell self-renewal and expansion in Drosophila [8, 9] .
In the canonical Hippo tumour suppressor signalling pathway, MST1/2 activates LATS1/2 phosphorylation at Thr1079/Thr1041 sites. Furthermore, MST1/2, stimulated by the scaffold protein SAV1, enhances the ability of MOB1 to bind LATS1/2 via the phosphorylation of MOB1, which also contributes to LATS1/2 activation. Activated LATS1/2 directly phosphorylates YAP at Ser127, leading to cytoplasmic sequestration by binding to 14-3-3 proteins and, thus, inactivation of YAP ( Fig. 1 ) [10] . Intriguingly, current evidence indicates that MST1/2 and LATS1/2 are not always required for the regulation of YAP/TAZ. In Drosophila, Misshapen (Msn) and Happyhour represses in parallel oncoprotein Yki nuclear activity by interacting with Wts [11] . The mammalian Msn homologue MAP4K family members such as MAP4K4, MAP4K3 have been identified to be alternative MST1/2 kinase, directly leading to the activation of LATS1/2. Combined ablation of MAP4K and MST1/2 abolished LATS1/2-mediated YAP cytoplasmic retention, leading to increased stem cells and cancer progression [12, 13] . Fig. 1 . The Hippo tumour-suppressor signalling pathway in mammals. When Hippo is on, MST1/2 activates LATS1/2 phosphorylation. MST1/2 that is supported by a scaffold protein SAV1 enhances MOB1's ability to bind LATS1/2 via the phosphorylation of MOB1, which also contributes to LATS1/2 activation. The activated LATS1/2 directly phosphorylates YAP, leading to cytoplasmic sequestration by binding to 14-3-3 protein and therefore inactivation of YAP. In contrast, when the Hippo pathway is off, YAP and TAZ are dephosphorylated and translocated into the nucleus. Subsequently, activated YAP/TAZ induce the expression of downstream effectors including CTGF, CYR61, AREG, MYC, and other proteins by interaction with transcriptional coactivator TEAD. Verteporfin and VGLL4 suppress the YAP-TEAD interaction.
In addition, Zhang et al. [14] reported that NDR1/2, as the closest homologue of LATS1/2, negatively affects colon cancer progression by effectively phosphorylating YAP at Serine 127 (Ser127).
In contrast, when the Hippo pathway is inactivated, YAP and TAZ are dephosphorylated and translocate to the nucleus. Subsequently, activated YAP/TAZ induce the expression of oncogenic cell proliferation and antiapoptotic genes through interaction with transcriptional coactivators, particularly TEA domain family members (TEAD) [15, 16] . Verteporfin, a new photosensitizer and a traditional chemotherapy agent for age-related macular degeneration, has recently been found to suppress the YAP-TEAD interaction and the overgrowth of liver tissue [17] (Fig. 1) . The studies in cultured cells and mice have revealed that constitutive expression or hyperactivation of YAP can contribute to the malignant phenotype of various cancers [18, 19] . MOB1A/1B double deletion in mice liver induces inflammatory cell infiltration and tissue growth in a YAP/TAZ-dependent manner, eventually resulting in liver cancer [20] .
The function of the Hippo pathway in cancer progression
Under normal physiological conditions, the Hippo pathway controls crucial cellular functions, such as cell proliferation, apoptosis, contact inhibition, cell-cell adhesion and stem cell expansion [21] . For example, high cell density leads to activation of Hippo pathway and phosphorylation of YAP. Consequently, YAP translocates to cytoplasm and accelerates cancer cells' contact inhibition [22] . Disruption of the Hippo signalling pathway is closely linked to cancer progression through the alteration of cellular characteristics. Uncontrolled cell proliferation and restrained apoptosis are responsible for neoplasia. Studies in animal models have suggested that conditional knockout of the upstream kinases of the Hippo pathway MST1/2 significantly contributes to the overgrowth of tissues and tumour formation. Higher YAP and TAZ levels have also been observed in different tumour types [19] . Ectopic expression or constitutive activation of the YAP oncogene promotes the proliferation of human cholangiocarcinoma cells by functionally interacting with TEADs [23] . The direct target genes of the YAP-TEAD complex, such as connective tissue growth factor (CTGF), cysteine-rich angiogenic inducer (CYR61), and MYC and amphiregulin (AREG), are considered to enhance cell proliferation [24, 25] (Fig. 1) . The Drosophila core module Yorkie has been demonstrated to promote cell proliferation and defective apoptosis by controlling the cell cycle proteins cyclin E and MYC [9, 26] . In addition to cell survival, abnormal Hippo signalling confers important advantages in tumorigenesis related to cell invasion and metastasis. YAP1, which is recognized as a poor prognostic marker, is reportedly highly involved in metastatic carcinoma [27] . Epithelial-mesenchymal transition (EMT) and deficient contact inhibition are hallmarks of a metastatic lesion. At a low growth density, knockout of LATS1 in non-invasive cancer cells restored the invasive phenotype. Furthermore, in vivo and in vitro studies have indicated that inhibition of YAP suppresses vascular invasiveness through upregulation of the cytokines interleukin 6 (IL-6), interleukin 8 (IL-8) and C-X-C motif chemokine 2 (CXCR2) [28] . In accordance with these studies, increased nuclear localization of TAZ functions as a transducer of the Hippo pathway and markedly induces EMT markers, with cooperation of the transcriptional factor TEAD, which drives cancer cells to dissociate from the primary tumour mass and contribute to subsequent cell invasiveness [29, 30] . The Hippo pathway is also critical for cell regeneration and stem cell properties. YAP is often enriched and activated in the epithelial compartments of the mammalian liver. As a result, mature differentiated epithelial cells can be reprogrammed for the generation of progenitors and liver overgrowth in a Notch signalling pathway-dependent manner [31] . Intestinal stem cell (ISC) regeneration has been closely linked to YAP-dependent reprogramming of Lgr5(+) stem cells [32] . Therefore, these data suggest that deregulation of the Hippo pathway promotes the tumorigenic potential by causing aberrant cancerrelated cell properties.
Regulation of the Hippo pathway
In recent years, evidence related to the regulation of the Hippo pathway has emerged. It has been documented that Merlin (also known as NF2), a member of the ezrin/radixin/moesin protein family, can promote the Hippo pathway via recruiting the intrinsic kinase to the plasma membrane [33] . Moreover, Gprotein-coupled receptors (GPCRs) have been revealed as potential mediators of Hippo signalling. In response to phospholipids, serum-borne lysophosphatidic acid and sphingosine 1-phosphate inhibit LATS1/2 activity by binding to Ga12/13-coupled receptors, which leads to dephosphorylation and activation of YAP/TAZ [34] . In addition to GPCRs, leukaemia inhibitory factor receptor (LIFR), a direct target of miR-9, has been found to suppress breast cancer invasion and metastasis through alteration of Scribble localization and phosphorylation-dependent inactivation of YAP [35] . Recently, a large body of evidence elucidating crosstalk between miRNAs and the Hippo pathway has emerged. miRNAs play an important role in the posttranscriptional or translational regulation of genes. In turn, the Hippo pathway controls miRNA biogenesis. Accordingly, in the following sections, we attempt to capture the complex relationship between miRNAs and the Hippo signalling pathway.
miRNAs
MicroRNAs were first identified in Caenorhabditis elegans through conventional forward genetic screening [36] . In recent years, it has become clear that miRNAs are involved in normal physiological processes, including cell proliferation, differentiation and apoptosis, as well as several pathological conditions, such as tumours. Indeed, it is now well established that miRNAs are a family of small noncoding RNAs of 21-25 nucleotides in length that negatively regulate protein expression at the post-transcriptional or translational level [37] .
Biogenesis of miRNAs
Mature human miRNAs are synthesized through a two-step process, in which one step takes place in the nucleus and the other in the cytoplasm [38] . The biogenesis of miRNA is a complex process (Fig. 2) . First, primary miRNA transcripts (pri-miRNA) with 5 0 cap structures and poly A tails are processed by RNA polymerase II [39] . The protein complex consisting of the RNase III enzyme Drosha and the double-stranded RNA-binding protein encoded by the DiGeorge syndrome critical region gene (DGCR8) known as a microprocessor, is required for the cleavage of primiRNA. DGCR8 recognizes the ssRNA-dsRNA junction of pri-miRNA and then drives Drosha to generate the 60-nucleotide precursor miRNA (pre-miRNA) [40, 41] . Subsequently, the pre-miRNA hairpin is transported from the nucleus to the cytoplasm by Exportin-5-Ran-GTP. In the cytoplasm, the pre-miRNAs are cleaved by the Dicer ribonuclease into a 21-23 nucleotide miRNA* duplex that contains both the mature miRNA strand and its complementary strand. The mature miRNAs are then incorporated into the RNAinduced silencing complex (RISC) together with Argonaute 2 [42] . As a result, the miRNAs reduce the post-transcriptional or translational levels of mRNAs by targeting the 3 0 UTR [43] .
Function of miRNAs in cancer
Many published reports have shown that the miRNA levels are altered in various types of cancer. miRNAs may function as either tumour suppressors or promoters, associated with changes in cancer cell biology processes and the microenvironment [44] . For example, miR-155 and miR-21 are the most frequently overexpressed miRNAs in malignant tumours. Downregulation or depletion of miR-21 results in reduced cell proliferation and tumour growth [45, 46] . Conversely, the miRNA Let-7, a well-known tumour suppressor, has been demonstrated to be highly reduced in both in vitro and in vivo cancer studies [47] . Specifically, loss of miR-7 is closely associated with a poor survival rate in patients through genetic amplification of the oncogene MYCN [48] .
Crosstalk between the Hippo pathway and miRNAs
Regulation of the biogenesis of miRNAs by the Hippo pathway
The crosstalk between the Hippo signalling pathway and miRNAs has been well documented in tumour development and progression. Recent data suggest that the Hippo signalling pathway affects miRNA biogenesis through a microprocessor complex in a cell densitydependent manner, which might provide novel mechanisms of the Hippo pathway in tumorigenesis [49] . Compared with cells grown at a high cell density, cells grown at a low density have been shown to effectively break from contact inhibition and invade an endothelial monolayer [28] . It is well known that pri-miRNA transcripts are cleaved into pre-miRNAs by the microprocessor complex. Dicer is responsible for pre-miRNA processing and the production of mature miRNAs [50] . Chaulk et al. reported that cell density-mediating nuclear expression of YAP/TAZ is required for high levels of Dicer to occur in MCF-10A cell lines. Mechanistically, Let-7, which is well validated as a tumour suppressor, is significantly attenuated by nuclear YAP/ TAZ levels. Increased nuclear YAP/TAZ can suppress the process of pre-miRNA conversion into mature Let-7 miRNA by mediating the Dicer enzyme [51, 52] . However, Let-7 biogenesis is dependent on cell density, rather than the expression of YAP/TAZ. Merlin is a typical upstream tumour suppressor of the Hippo pathway in Drosophila and mammals. Knockout of YAP in multiple tissues significantly decreases Merlin-deficient phenotypes [53] . A low cell density or deficient cell-cell contact contributes to the phosphorylation of Merlin, which permits Lin28 to enter the nucleus. The nuclear localization of Lin28, which is known as an inhibitor of Let-7 miRNA, leads to binding of Lin28 to pri-Let-7 and results in reduced Let-7 maturation [54, 55] . Additionally, the major transcriptional inducer of the Hippo pathway has been found to cause widespread repression of miRNAs through an interaction with p72 (also known as DDX17), which has led to the identification of a VCAUCH sequence motif in the 3 0 flanking region of pri-miRNA [4] (Fig. 2) . The association between YAP and p72 is also dependent on the cell density in the culture system. At a low cell density, nuclear localization of YAP sequesters p72 from the microprocessor complex and thereby inhibits miRNA biogenesis. Conversely, at a high cell density, inactivation of YAP enhances p72 binding to the microprocessor complex and augments miRNA expression. The induction of MYC, an important downstream oncogene of YAP leading to transcriptional repression of miRNAs, might be the mechanism underlying the reduction of miRNA biogenesis by YAP [56] .
However, a genome-wide miRNA microarray analysis has identified some miRNAs upregulated by YAP, particularly in the miR-29 family. The phosphatase and tensin homologue (PTEN) is a key regulator targeting the crosstalk between the Hippo and mTOR pathways. Ectopic expression of YAP markedly reduces endogenous PTEN protein levels. Studies have shown that knockdown of Dicer with siRNAs promotes the expression of PTEN in YAP-overexpressing cells suggest that miRNAs are important for the regulation of PTEN by YAP. The miR-29 family consists of three members: miR-29a, miR-29b and miR-29c. Previous studies have shown that PTEN is regulated by both miR-29a and miR-29b [57] . Further evidence may support the hypothesis that miR-29c inhibits PTEN translation by targeting the 3 0 UTR. Transient overexpression of miR-29 can rescue the effects of YAP knockdown on PTEN [58] . Taken together, these findings help to illuminate the role of miRNAs in Hippo signalling-associated cell overproliferation and tumorigenesis [59] .
Bantam miRNA
Bantam miRNA, a 21-nucleotide miRNA encoded by the bantam gene in Drosophila, has been demonstrated to stimulate cell proliferation and suppress apoptosis and stem cell self-renewal [60] . Yki is a key functional effector of the Hippo pathway in Drosophila and is a homologue of mammalian YAP. In Drosophila, Yki is responsible for the overgrowth of tissues through promoting cyclin E and the anti-apoptosis factor DIPAI. Bantam miRNA appears to be an important target of Yki and is essential for Yki-induced cell proliferation and antiapoptosis effects. Overexpression of bantam miRNA has been demonstrated to rescue cell survival and proliferation in Yki-mutant cells [61, 62] . In addition, the proliferation of Drosophila ISCs in response to the Hippo pathway is dependent on bantam miRNA. Knockdown of bantam miRNA suppresses the Yki-induced autonomous production of ISCs, but not the noncell-autonomous proliferation of ISCs [63] .
Oncogenic miRNAs as negative regulators of the Hippo pathway
Numerous studies have indicated that several miRNAs negatively regulate the Hippo tumour-suppressor signalling pathway and promote tumour progression ( Fig. 2; Table 1 ). miR-31 is an oncogenic miRNA that has been found to be prominently overexpressed in murine and human cancers [64] . Overexpression of miR-31 directly represses the level of LATS2 posttranscriptionally by targeting the 3 0 UTR in the HEC-50B human endometrial cancer cell line. Consequently, the transcriptional activator YAP1 is activated and translocates to the nucleus, targeting the expression of downstream effectors associated with cell proliferation and antiapoptosis effects, such as cyclin D1, RAS, and XIAP [65] . Another miRNA linked to LATS2 is miR-135b. The antioncogenes LATS2 and MOB1 in the Hippo signalling pathway may be coincidently inhibited by miR-135b. Patients with nonsmall cell lung cancer express higher levels of miR-135b and nuclear TAZ, but lower levels of LATS2, which is highly correlated with poor overall survival. In lung cancer cells, an miR-135b antagomir was shown to induce Hippo pathway activation by controlling LATS2 and NDR2. As a result, the proliferation and metastasis of the cancer cells were inhibited [66] .
Leukaemia inhibitory factor receptor is a breast cancer metastasis suppressor that is upstream of the Hippo pathway [35] . Given that miR-125a has been characterized as a tumour suppressor that inhibits cancer invasion and metastasis in cervical cancer by targeting STAT3, hyperactivation of miR-125a may also yet contribute to perturbation of the Hippo signalling pathway and, thus, to high levels of the nuclear transcriptional activator TAZ, resulting in the expansion of human breast cancer stem cells [67, 68] .
Interestingly, several miRNAs have been demonstrated to form a feedback loop with the transinducer YAP. Widespread upregulation of the miR-130 family has been found in several types of cancer, including bladder cancer, oesophageal squamous cell carcinoma and gastric cancer [69, 70] . Part of the reason for this association might be that the miR-130 family is involved in a variety of cancer cell biological processes that regulate PTEN expression and Akt phosphorylation. Both in vivo and in vitro studies have indicated that the miR-130 levels are induced by YAP. In turn, upregulation of miR-130 reduces the expression of VGLL4, which negatively regulates the formation of the YAP-TEAD complex, thereby augmenting nuclear YAP activity [71] . Overgrowth and tumorigenesis of liver tissue have been attributed to the positive feedback loop between miR-130 and YAP [72] . Similarly, overexpression of miR-130 results in activation of YAP/TAZ and several downstream genes of the Hippo signalling pathway (CTGF, MYC and BMI1), which is accompanied by an increase in the malignant phenotype of glioblastoma [73] . In addition, miR-206 functions as a tumour suppressor and appears to block cell cycle progression, proliferation, invasion and migration [74] . Microarray assays have shown that YAP [87] increases the expression of miR-206. In turn, miRNA-206 plays an important role in mediating YAP function [75] .
Tumour-suppressor miRNAs as positive regulators of the Hippo pathway
It has been demonstrated that inactivation of the tumour-suppressive Hippo signalling pathway induces nuclear location and activation of YAP/TAZ and contributes to tumorigenesis. Many miRNAs that are known as tumour suppressors are also involved in the regulation of cancer cell biological processes, including cell proliferation, the cell cycle, apoptosis pathways and metastasis, by targeting YAP or TAZ ( Fig. 2 ; Table 1 ). The expression of miR-375 is significantly reduced in tumour tissues compared with adjacent nontumour tissues of individuals with hepatocellular carcinoma (HCC). Luciferase and immunoblotting assays have suggested that miR-375 may directly target the 3 0 UTR of YAP1 mRNA, leading to the inhibition of pancreatic progenitor and HCC cells. CCK8 and Ki-67 experiments have shown that the transfection of siYAP1 and miR-375 mimics into cells obviously inhibits the proliferation of pancreatic progenitor cells, suggesting that miRNAs are involved in the regulation of stem/progenitor cell proliferation [76, 77] . Furthermore, another miRNA with an important role in regulating YAP expression is miR-186, which directly targets YAP1, thereby suppressing YAP1 levels and regulating the Hippo signalling pathway [78] .
More recently, miR-9 and miR-137 have been reported to suppress the translation of CUL4A, which is amplified or overexpressed in various carcinomas and contributes to cancer metastasis. Ectopic miR-9 and miR-137 promote the expression of LATS1 and phosphorylated YAP, which further upregulate downstream factors such as CTGF, CYR61 and AREG in gastric cancer progression [79] . Additionally, in HCC cells, miR-9-3p, which is processed from the 3 0 arm of miR-9, has been shown to inhibit the expression of TAZ, a well-known cancer-promoting factor downstream of the Hippo pathway [80] . Lower levels of miR-129-5p are correlated with poor survival and malignant cancer progression [81] . Because downregulation of miR-129-5p directly results in the activation of the oncogenic transcriptional activators and effectors of the Hippo pathway YAP/TAZ and contributes to their interaction with TEAD. These findings suggest that the activation of the Hippo pathway is required for the anticarcinogenic effect of miR-129-5p [82] .
Another important miRNA that targets TAZ is miRNA-125a-5p. Recently, inactivation of miR-125a-5p was identified in cancer cell lines, including HCC and breast cancer cells, among others. Moreover, miR-125a-5p might serve as a prognostic biomarker because it is closely associated with tumour grade, lymphatic metastasis, and survival rates [83] . Intriguingly, overexpression of miR-125a-5p attenuates the EGFR pathway by targeting the 3 0 UTR of TAZ to suppress retinoblastoma tumorigenesis [84] . Additionally, the expression of TAZ target genes such as CTGF and survivin is induced by TAZ, which triggers the downregulation of glioblastoma cell proliferation and stimulates cell differentiation [85] . Moreover, miR-338-3p targets TAZ and regulates the tumorigenesis of HCC. Human HCC cell lines transiently transfected with miR-338-3p mimics show inhibition of TAZ levels. In contrast, transfection with miR-338-3p inhibitors results in increased expression of TAZ. In addition, when cells were transfected with a TAZ 3 0 UTR-wild plasmid or a 3 0 UTR-mutant plasmid, exogenous miR-338 was shown to significantly reduce the reporter activity of the TAZ 3 0 UTR-wild plasmid compared with the TAZ 3 0 UTR-mutant plasmid [86] . The E3 ubiquitin ligase ITCH has been reported to inhibit the Hippo pathway via downregulation of LATS1/2. Luo et al. [87] have indicated that miR-106b indirectly affects the Hippo pathway through targeting ITCH repression, which plays a crucial role in the metastatic progression of pancreatic cancer. Cumulatively, both oncogene miRNAs and anti-oncogene miRNAs that regulate the Hippo pathway play complicated roles in tumorigenesis.
Conclusions and perspectives
MicroRNAs play crucial roles in cancer initiation and progression including the acquisition of EMT and cancer stem cell phenotypes. More speculatively, miRNAs have been identified as novel diagnostic and prognostic biomarkers as well as targets for tumour therapy. Emerging evidence has suggested that the complicated crosstalk between miRNAs and the Hippo signalling pathway contributes to tumorigenesis. In mammals, the Hippo pathway may strongly regulate miRNA biogenesis in a Dicer-or p72-dependent manner. Recently, a group of miRNAs have been demonstrated to directly target components of the Hippo signalling pathway, such as YAP, TAZ and LATS1/2.
Although large-scale studies have been devoted to identifying miRNAs as well as their mRNA targets and their contribution to the regulatory Hippo pathway, we have just scratched the surface of this topic. The biological functions and regulatory relationships between miRNAs and their targets can easily be explored; however, many of these relationships are complex and context specific. Therefore, it is critically important to analyse the underlying molecular mechanisms through which the perturbation of this crosstalk affects tumour progression. Delineating these interactions may have useful clinical implications for the prevention and treatment of human cancers in the future.
